Your session is about to expire
← Back to Search
Letermovir tablet for Cytomegalovirus
Study Summary
This trial is testing the effects of a drug called letermovir on different age groups of children. All participants will take the drug for 14 weeks.
- Cytomegalovirus (CMV)
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 65 Patients • NCT03940586Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any opportunities currently available to participate in this experiment?
"The clinicaltrials.gov database divulges that this trial, which was first advertised on August 8th 2019 and last altered on November 22nd 2022, is not actively seeking new participants. However, there are 798 other trials currently accepting patients at the moment."
What is the cap on participant capacity for this clinical investigation?
"This trial has concluded recruitment, having been initially posted on August 8th of 2019 and last edited November 22nd 2022. If you are currently seeking a clinical study to join, 791 investigations for infections and 7 trials regarding Letermovir tablets are actively recruiting participants at this time."
What goals is this clinical trial attempting to accomplish?
"This research will be assessed within a seven-day window and its primary goal is to measure the Area under the concentration-time curve of plasma letermovir for oral formulation. Additionally, secondary outcomes include quantifying participants who discontinued study medication due to an AE, those with one or more adverse events (AEs), and individuals with clinically significant CMV infection through Week 24 post-transplant."
Could you provide a synopsis of earlier research using Letermovir tablet?
"Presently, there are 7 clinical trials being conducted for the Letermovir tablet. None of these studies have entered Phase 3 yet. The majority of tests are occurring in Columbus, Ohio; however, 67 different sites across the United States and beyond are researching this medication's efficacy."
How can the ingestion of Letermovir tablet potentially harm a patient?
"The safety profile of Letermovir tablets was assessed by our team at Power and determined to be a 2. This is due to the fact that this medication has been evaluated in Phase 2 trials, providing some evidence surrounding its security but none pertaining to effectiveness."
Are there a significant number of North American locations involved in the implementation of this research?
"At the moment, 11 clinical sites are actively running this trial. These locations include Chicago, Dallas and San Francisco among others. To reduce transportation strain, it is important to select an available site that is close to you if enrolling in the trial."
Does this clinical experiment represent an unprecedented approach?
"Merck Sharp & Dohme LLC initiated the initial trial for Letermovir tablet in 2019, which involved 86 participants. Following successful results from this Phase 1 study, a stronger drug approval was granted and now there are 7 active studies of the medication occurring across 34 cities and 11 countries."
Share this study with friends
Copy Link
Messenger